Skip to main navigation Skip to search Skip to main content

Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease

  • Jason A Tye-Din
  • , Jessica A Stewart
  • , James A Dromey
  • , Tim Beissbarth
  • , David A van Heel
  • , Arthur Tatham
  • , Kate Henderson
  • , Stuart I Mannering
  • , Carmen Gianfrani
  • , Derek P Jewell
  • , Adrian VS Hill
  • , James McCluskey
  • , Jamie Rossjohn
  • , Robert P Anderson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Celiac disease is a genetic condition that results in a debilitating immune reaction in the gut to antigens in grain. The antigenic peptides recognized by the T cells that cause this disease are incompletely defined. Our understanding of the epitopes of pathogenic CD4(+ )T cells is based primarily on responses shown by intestinal T-cells in vitro to hydrolysates or polypeptides of gluten, the causative antigen. A protease-resistant 33-amino acid peptide from wheat alpha-gliadin is the immunodominant antigen, but little is known about the spectrum of T cell epitopes in rye and barley or the hierarchy of immunodominance and consistency of recognition of T-cell epitopes in vivo. We induced polyclonal gluten-specific T cells in the peripheral blood of celiac patients by feeding them cereal and performed a comprehensive, unbiased analysis of responses to all celiac toxic prolamins, a class of plant storage protein. The peptides that stimulated T cells were the same among patients who ate the same cereal, but were different after wheat, barley and rye ingestion. Unexpectedly, a sequence from omega-gliadin (wheat) and C-hordein (barley) but not alpha-gliadin was immunodominant regardless of the grain consumed. Furthermore, T cells specific for just three peptides accounted for the majority of gluten-specific T cells, and their recognition of gluten peptides was highly redundant. Our findings show that pathogenic T cells in celiac disease show limited diversity, and therefore suggest that peptide-based therapeutics for this disease and potentially other strongly HLA-restricted immune diseases should be possible.
Original languageEnglish
Pages (from-to)1 - 14
Number of pages14
JournalScience Translational Medicine
Volume2
DOIs
Publication statusPublished - 2010

Cite this